Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Newron Pharmaceuticals SpA    NWRN   IT0004147952

NEWRON PHARMACEUTICALS SPA (NWRN)
My previous session
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Swiss Exchange
08/10/2018 08/13/2018 08/14/2018 08/15/2018 08/16/2018 Date
11.22(c) 11.22(c) 11.5(c) 10.68(c) 10.66(c) Last
38 076 13 421 25 306 36 737 29 831 Volume
+2.00% 0.00% +2.50% -7.13% -0.19% Change
More quotes
Financials (EUR)
Sales 2018 7,87 M
EBIT 2018 -19,5 M
Net income 2018 -19,4 M
Finance 2018 42,5 M
Yield 2018 -
Sales 2019 22,9 M
EBIT 2019 -17,2 M
Net income 2019 -17,0 M
Finance 2019 19,7 M
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales2018 16,1x
EV / Sales2019 6,52x
Capitalization 169 M
More Financials
Company
Newron Pharmaceuticals SpA is a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system.Its products include Xadago for Parkinson's disease; sarizotan for patients with Rett syndrome; and ralfinamide for... 
More about the company
Surperformance© ratings of Newron Pharmaceuticals SpA
Trading Rating : Investor Rating :
More Ratings
Latest news on NEWRON PHARMACEUTICALS SPA
08/01NEWRON PHARMACEUTICALS : to Present at Wedbush PacGrow Healthcare Conference
BU
06/21NEWRON PHARMACEUTICALS : Provides Update on STARS Clinical Study with Sarizotan ..
AQ
06/14NEWRON PHARMACEUTICALS : Provides Update on STARS Clinical Study with Sarizotan ..
AQ
06/13NEWRON PHARMACEUTICALS : Provides Update on STARS Clinical Study with Sarizotan ..
BU
06/13Newron provides update on STARS clinical study with sarizotan for the treatme..
TE
06/13NEWRON PHARMACEUTICALS : provides update on STARS clinical study with sarizotan ..
PU
05/29NEWRON PHARMACEUTICALS : to Present at Jefferies 2018 Healthcare Conference
BU
05/15NEWRON PHARMACEUTICALS : to Present at the UBS Global Healthcare Conference 2018
BU
03/27NEWRON PHARMACEUTICALS : Announces Shareholders Accepted All Motions at the AGM ..
BU
03/27Shareholders accepted all motions at the AGM 2018
TE
More news
Sector news : Bio Therapeutic Drugs
08/16REGENERON PHARMACEUTICALS : Teva Report Positive Phase 3 Fasinumab Results
DJ
08/03Roche Drug for Brain Disease Granted European Fast-Track
DJ
08/02Regeneron Closes Up 7% After 2Q Earnings Beat -- Data Talk
DJ
08/02REGENERON PHARMACEUTICALS : Beats Earnings Estimates
DJ
07/31UNITED THERAPEUTICS : Medtronic Get FDA OK for Remodulin Implantable System
DJ
More sector news : Bio Therapeutic Drugs
Latest Tweets
05/29Newron Pharmaceuticals to Present at Jefferies 2018 Healthcare Conference  
05/26Critical Survey: Newron Pharmaceuticals $NWPHF versus Dicerna Pharmaceuticals.. 
05/15Newron Pharmaceuticals to Present at the UBS Global Healthcare Conference 201.. 
05/15Newron Pharmaceuticals : to Present at the UBS Global Healthcare Conference 2.. 
04/04$NWRN Pharmaceuticals Spa. Newron Pharmaceuticals - 2018 focus on the CNS pi..
1
More tweets
Qtime:23
News from SeekingAlpha
03/01Newron Pharmaceuticals SPA reports FY results 
2017Newron Pharmaceuticals SPA reports 1H results 
2017Newron Pharmaceuticals SPA reports FY results 
2016FDA accepts for review Newron's resubmitted NDA for Xadago; action date March.. 
2016Newron Pharmaceuticals SPA reports 1H results 
Chart NEWRON PHARMACEUTICALS SPA
Duration : Period :
Newron Pharmaceuticals SpA Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NEWRON PHARMACEUTICALS SPA
Short TermMid-TermLong Term
TrendsBearishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 3
Average target price 24,2 €
Spread / Average Target 155%
EPS Revisions
Managers
NameTitle
Stefan Weber Chief Executive Officer, Director & IR Contact
Ulrich Köstlin Non-Executive Chairman
Roberto Galli Vice President-Finance
Ravi Anand Chief Medical Officer
Patrick J. Langlois Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
NEWRON PHARMACEUTICALS SPA-7.93%193
GILEAD SCIENCES7.91%100 220
VERTEX PHARMACEUTICALS17.40%44 961
REGENERON PHARMACEUTICALS-2.59%38 873
NEUROCRINE BIOSCIENCES, INC.49.79%10 514
GENMAB1.46%9 810